Program

NSGO-CTU Biannual Investigator Meeting
28-29 November 2019

Radisson Blu Scandinavia Hotel, Copenhagen
Amager Blvd. 70, 2300 København

This meeting is partly sponsored by
Thursday 28 November 2019
18.00 – 1900 Buffet
19.00 – 21.20 NSGO-CTU Symposium
Chair: Johanna Mäenpää, Tampere, Finland

PARP inhibitors in combination
19.00 – 19.20 Rationale and clinical evidence of PARP inhibitors in combination with other novel agents, Mansoor Raza Mirza, NSGO-CTU
19.20 – 20.00 PAOLA study results and beyond, Eric Pujade-Lauraine, GINECO, France
20.00 – 20.20 Translation research in PARP inhibitor, Line Bjørge, Bergen, Norway
20.20 – 21.20 Panel discussion
   Eric Pujade-Lauraine, GINECO, France
   Johanna Mäenpää, Tampere, Finland
   Susanne Malander, Lund, Sweden
   Line Bjørge, Bergen, Norway
   Henrik Roed, Copenhagen, Denmark
   Ingvild Vistad, Kristiansand, Norway
   Mansoor Raza Mirza, NSGO-CTU

NSGO-CTU Scientific Symposium is an official part of NSGO-CTU Biannual Investigator meeting program with NSGO-CTU being solely responsible for the content. The Symposium is supported by a sponsorship from a pharmaceutical company.

Friday 29 November 2019
07.30 – 08.00 Registration/coffee
08.00 – 09.40 NSGO-CTU Symposium
Chair: Kristina Lindemann, Oslo, Norway

Patient’s perspective
08:00 – 08:40 Patient’s acceptance of novel treatments, Jalid Sehouli, Berlin, Germany
08:40 – 08:55 Patient’s view, Birthe Lemley, KIU, Denmark
08:55 – 09:10 “No decision about me – without me” – Shared decision making as a concept, Karina Dahl Steffensen, Vejle, Denmark
09:10 – 09:25 The role of patient-reported outcomes in palliation, Kristina Lindemann, Oslo, Norway
09:25 – 09.45 Panel Discussion
   Jalid Sehouli, Berlin, Germany
   Maria Dimoula, Sahlgrenska, Sweden
   Karina Dahl Steffensen, Vejle, Denmark
   Annika Auranen, Tampere, Finland
   Gitte-Bettina Nyvang, Odense, Denmark

NSGO-CTU Scientific Symposium is an official part of NSGO-CTU Biannual Investigator meeting program with NSGO-CTU being solely responsible for the content. The Symposium is supported by a sponsorship from a pharmaceutical company.
10.00 – 10.05 Welcome
    Mansoor Raza Mirza, NSGO-CTU

10.05 – 10.15 Future plans and status report of NSGO-CTU activities, Mansoor Raza Mirza, NSGO-CTU

OVARIAN CANCER
10.15 – 10.45 Surgical trials – Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact.
    Chair: Johanna Mäenpää, Tampere, Finland

10.15 – 10.25 Overview of Surgical trials:
    - AGO-OVAR OP.4/DESKTOP III
    - TRUST
    Johanna Mäenpää, Tampere, Finland

10.25 – 10.35 OVHIPEC-2
    Berit Jul Mosgaard, Copenhagen, Denmark

10.35 – 10.45 Panel discussion
    Ulla Puistola, Oulu, Finland
    Päivi Lindvall Kannisto, Lund, Sweden
    Yun Wang, Oslo, Norway
    Berit Jul Mosgaard, Copenhagen, Denmark

OVARIAN CANCER
10.45 – 11.45 First line trials - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome
    Chair: Henrik Roed, Copenhagen, Denmark

10.45 – 11.00 Overview of First line trials:
    - AGO-OVAR 17/BOOST
    - AGO-OVAR12
    - AGO-OVAR16
    - ENGOT-ov39/IMagyn050
    - ENGOT-ov25/PAOLA-1
    - PRIMA/ENGOT-OV26/GOG-3012
    Henrik Roed, Copenhagen, Denmark

11.00 – 11.10 ENGOT-ov44/First - An adaptive Randomized Phase 3 Comparison of Standard Platinum Based Treatment Versus Platinum and TSR-042 followed by Niraparib and TSR-042 maintenance Therapy in Patients with epithelial Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum
    Gitte-Bettina Nyvang, Odense, Denmark
11.10 – 11.20 **DUO-O** - Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients
_Maarit Anttila, Kuopio, Finland_

11.20 – 11.30 **ENGGT-ov45/NCRI/ATHENA** - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy
_Susanne Malander, Lund, Sweden_

11.30 – 11.45 Panel discussion
_Gitte-Bettina Nyvang, Odense, Denmark_
_Maarit Anttila, Kuopio, Finland_
_Susanne Malander, Lund, Sweden_
_Henna Kärkkäinen, Kuopio, Finland_
_Kristine Madsen, Copenhagen, Denmark_
_Nicoline Raaschou-Jensen, Herlev, Denmark_
_Birute Brasiuniene, Vilnius, Lithuania_

**OVARIAN CANCER**

11.45 – 12.40 **Relapsed disease** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome
_Chair: Line Bjørge, Bergen, Norway_

11.45 – 11.55 **Overview of trials where platinum is an option:**
- **INOVATYON**
- **ENGGT-ov16/NOVA**
- **ENGGT-ov24-NSGO/AVANOVA**
- **ENGGT-ov38/OREO**
_Line Bjørge, Bergen, Norway_

11.55 – 12.05 **ENGGT-OV42-NSGO/AVATAR** – A three-arm randomized study to evaluate the efficacy of niraparib-bevacizumab-dostarlimab triplet combination against niraparib-bevacizumab doublet combination and against standard of care therapy in Women with relapsed ovarian cancer where platinum combination therapy is an option.
_Mansoor Mirza, NSGO-CTU_
12.05 – 12.20 **Panel discussion**

*Synnöve Staff, Tampere, Finland*
*Hanna Dahlstrand, Uppsala, Sweden*
*Morten Jørgensen, Rigshospitalet, Denmark*
*Elisabeth Berge Nilsen, Stavanger, Norway*
*Mansoor Raza Mirza, NSGO-CTU*

**LUNCH** 12.20-13.20

**OVARIAN CANCER**

13.20 – 13.40 **Relapsed disease** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome

*Chair: Annika Auranen, Tampere, Finland*

13.20 – 13.30 **ENGOT-ov34/2.29** – Atezolizumab in combination with Bevacizumab and Chemotherapy versus Chemo-Bevacizumab standard in recurrent ovarian cancer – a randomized Phase III trial

*Sakari Hietanen, Turku, Finland*

13.30 – 13.40 **ENGOT-ov30/NSGO-UMBRELLA** – A multicenter, phase 2, open-label non-randomized study to obtain preliminary evidence of efficacy of several novel combinations in relapsed ovarian cancer. This information regards Cohorte A, MEDI9447 and Durvalumab

*Liv Cecilie Vestrheim Thomsen, Bergen, Norway*

13.40 – 13.50 **Panel discussion**

*Sakari Hietanen, Turku, Finland*
*Mansoor Raza Mirza, NSGO-CTU*
*Liv Cecilie Vestrheim Thomsen, Bergen, Norway*
*Ulla Puistola, Oulu, Finland*
*Elisabeth Berge Nilsen, Stavanger, Norway*
*Gerli Kuusk, Tallinn, Estonia*

**ENDOMETRIAL CANCER**

13.50 – 14.45 **Endometrial Cancer** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome

*Chair: Caroline Lundgren, Karolinska, Sweden*

13.50 – 14.00 **ENGOT-EN2-DGCG** – A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer

*Bente Lund, Aalborg, Denmark*
14.00 – 14.10 **ENGOT-EN1/FANDANGO** – A Randomized Phase II Trial of First-line Combination Chemotherapy with Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer
*Hanna Dahlstrand, Uppsala, Sweden*

14.10 – 14.20 **ENGOT-EN3-NSGO/PALEO** – A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer
*Anne Dørum, Oslo, Norway*

*Mansoor Raza Mirza, NSGO-CTU*

14.30 – 14.45 **Panel discussion**
*Bente Lund, Aalborg, Denmark*
*Hanna Dahlstrand, Uppsala, Sweden*
*Anne Dørum, Oslo, Norway*
*Mansoor Raza Mirza, NSGO-CTU*
*Marjut Rintala, Turku, Finland*
*Kathrine Woie, Bergen, Norway*
*Karin Grisan, Tartu, Estonia*

**COFFEE 14.45 – 15.05**

**CERVICAL and VULVAR CANCER**
15.05 – 16.30 **Cervical Cancer** - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome
*Chair: Ane Gerda Zahl Eriksson, Oslo, Norway*

15.05 – 15.15 **Update of minimal invasive surgery – RACC trial**
*Sahar Salehi, Stockholm, Sweden*

15.15 – 15.25 **ENGOT-cx7-NSGO/MaRuC**
**ENGOT-cx11** – A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer
*Mansoor Raza Mirza, NSGO-CTU*

15.25 – 15.35 **ENGOT-cx10/GEICO 68-C/BEAT cc** – A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix
*Kristina Lindemann, Oslo, Norway*
15.35 – 15.45 **ENGOT-cx13/AGO/FERMATA** – An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer
*Farrukh Chaudhary, Herlev, Denmark*

15.45 – 15.55 **ENGOT-cx6** – Tisotumab Vedotin in Previously treated recurrent or metastatic cervical cancer.
**ENGOT-cx8** – Randomized, open label, phase 1b/2 first line trial with Tisotumab Vedotin.
**ENGOT-cx12** – A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer.
*Lars Fokdal, Århus, Denmark*

15.55 – 16.05 **GROINSS V III**
*Kristina Lindemann, Oslo, Norway*

16.05 – 16.15 **PEACE** – Palliation in gynae-oncology: Evaluation and Assessment of satisfaction with care
*Kristina Lindemann, Oslo, Norway*

16.15 – 16.30 **Panel discussion**
*Sahar Salehi, Stockholm, Sweden*
*Mansoor Raza Mirza, NSGO-CTU*
*Kristina Lindemann, Oslo, Norway*
*Farrukh Chaudhary, Herlev, Denmark*
*Lars Fokdal, Århus, Denmark*
*Johanna Määnpää, Tampere, Finland*
*Birute Brasiuniene, Vilnius, Lithuania*

16.30 – 16.40 **End of meeting**
*Mansoor Raza Mirza, NSGO-CTU*

NSGO-CTU will reimburse travel expenses maximum 200 Euros each for one investigator and one research nurse from an NSGO site.